NCT06159673

ACP-204 in Adults With Alzheimer's Disease Psychosis

A Master Protocol for Three Independent, Seamlessly Enrolling, Double-blind, Placebo-controlled Efficacy and Safety Studies of ACP-204 in Adults With Alzheimer's Disease Psychosis

• Status: Recruiting
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 1,074 (estimated)
• Sponsor: ACADIA Pharmaceuticals Inc. · Industry
• Sex: All
• Age: 55 Years – 95 Years
• Healthy volunteers: Not accepted

Summary

This is a master protocol for 3 independent, seamlessly enrolling, multicenter, randomized, double-blind, placebo-controlled, parallel-group studies in patients with ADP * Substudy 1 (Phase 2) will evaluate efficacy and dose response of ACP-204 30 and 60 mg vs placebo. This substudy will be initiated first. * Substudies 2A and 2B (both: Phase 3) will be confirmatory studies of either both doses (ACP-204 30 and 60 mg, respectively) or a single dose from Part 1 vs placebo. Substudies 2A and 2B will be performed independently of each other and will commence after enrollment of Part 1. All 3 substudies will be analyzed independently of each other. Each substudy individually will consist of a screening period (up to 49 days); a double-blind treatment period (6 weeks); a safety follow-up period (30 days) for patients not rolling over into an open-label extension study; and vital status follow-up (for patients who terminated their substudy early).

Conditions

• Alzheimer's Disease Psychosis

Interventions

Type	Name	Description
DRUG	ACP-204	ACP-204 is a potent and selective antagonist/inverse agonist of 5-hydroxytryptamine (serotonin) receptor subtype 2A.
DRUG	Placebo	ACP-204 matching placebo

Timeline

• Start date: 2023-11-14
• Primary completion: 2028-01-01
• Completion: 2028-02-01
• First posted: 2023-12-07
• Last updated: 2026-04-15

Locations

145 sites across 12 countries: United States, Brazil, Bulgaria, Chile, Czechia, France, Italy, Mexico, Serbia, South Korea, Spain, Taiwan

Regulatory

• FDA-regulated drug study